Search Results - "Porrata, L.F."

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma by Witzig, T E, Reeder, C B, LaPlant, B R, Gupta, M, Johnston, P B, Micallef, I N, Porrata, L F, Ansell, S M, Colgan, J P, Jacobsen, E D, Ghobrial, I M, Habermann, T M

“…The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin's lymphoma (NHL)…”
Get full text

Bowel perforation in intestinal lymphoma: incidence and clinical features by Vaidya, R., Habermann, T.M., Donohue, J.H., Ristow, K.M., Maurer, M.J., Macon, W.R., Colgan, J.P., Inwards, D.J., Ansell, S.M., Porrata, L.F., Micallef, I.N., Johnston, P.B., Markovic, S.N., Thompson, C.A., Nowakowski, G.S., Witzig, T.E.

“…Perforation is a serious life-threatening complication of lymphomas involving the gastrointestinal (GI) tract. Although some perforations occur as the initial…”
Get full text

Incidence of Cardiac Arrhythmias During Autologous Peripheral Blood Stem Cell Transplantation by Singla, A, Hogan, W.H, Ansell, S.M, Buadi, F.K, Dingli, D, Dispenzieri, A, Gastineau, D.A, Gertz, M.A, Hayman, S.R, Inwards, D.J, Johnston, P.B, Lacy, M.Q, Litzow, M.R, Micallef, I.N, Porrata, L.F, Kumar, S.K

Get full text

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study by Nowakowski, G S, LaPlant, B, Habermann, T M, Rivera, C E, Macon, W R, Inwards, D J, Micallef, I N, Johnston, P B, Porrata, L F, Ansell, S M, Klebig, R R, Reeder, C B, Witzig, T E

“…Lenalidomide was shown to have significant single-agent activity in relapsed aggressive non-Hodgkin's lymphoma (NHL). We conducted a phase I trial to establish…”
Get full text

Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center by Dispenzieri, A, Seenithamby, K, Lacy, M Q, Kumar, S K, Buadi, F K, Hayman, S R, Dingli, D, Litzow, M R, Gastineau, D A, Inwards, D J, Micallef, I N, Ansell, S M, Johnston, P B, Porrata, L F, Patnaik, M M, Hogan, W J, Gertz, M A A

“…The underlying plasma cell clones in multiple myeloma (MM) and Ig light-chain amyloidosis (AL) appear to be different not only in terms of ‘tumor burden’ but…”
Get full text

Day 15 Interleukin 15 Levels Affect Natural Killer Cell Recovery After Autologous Stem Cell Transplantation by Porrata, L.F, Inwards, D.J, Micallef, I.N, Johnston, P.B, Ansell, S.M, Markovic, S.N

Get full text

A Cost Effective Analysis of a Risk-Adapted Algorithm for Plerixafor Use in Autologous Peripheral Blood Stem Cell Mobilization by Micallef, I.N, Sinha, S, Gastineau, D.A, Wolf, R, Inwards, D.J, Gertz, M.A, Hayman, S.R, Hogan, W.J, Johnston, P.B, Lacy, M.Q, Ansell, S.M, Buadi, F, Dingli, D, Dispenzieri, A, Litzow, M.R, Porrata, L.F, Winters, J.L, Kumar, S

Get full text

90: Autologous Stem Cell Transplant (ASCT) in First Remission for Patients with Mantle Cell Lymphoma is Associated with Prolonged Survival by Siddiqui, M.A, Johnston, P.B, Inwards, D.J, Ansell, S.M, Porrata, L.F, Micallef, I.N

Get full text

178: Improved Survival for Patients Undergoing Autologous Stem Cell Transplant in First or Later Remission for Primary CNS Lymphoma by Johnston, P.B, O'Neill, B.P, Ansell, S.M, Inwards, D.J, Porrata, L.F, Micallef, I.N.M

Get full text

Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning by DeCook, L J, Thoma, M, Huneke, T, Johnson, N D, Wiegand, R A, Patnaik, M M, Litzow, M R, Hogan, W J, Porrata, L F, Holtan, S G

“…We have recently shown that lymphocyte and monocyte recovery by day +100 are associated with survival post myeloablative allogeneic hematopoietic transplant…”
Get full text

89: Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study by Porrata, L.F, Inwards, D.J, Ansell, S.M, Micallef, I.N, Johnston, P.B, Gastineau, D.A, Litzow, M.R, Markovic, S.N

Get full text

CD34+ Cell Dose and Full Donor Chimerism at Day +100 Is Associated with Survival in Patients Who Received Reduced-Intensity Conditioning (RIC) With Fludarabine/Melphalan Prior To Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies by Holtan, S.G, Hogan, W.J, Elliott, M.A, Gastineau, D.A, Call, T.G, Ansell, S.A, Inwards, D.J, Johnston, P.B, Lacy, M.Q, Micallef, I.N, Porrata, L.F, Tefferi, A, Litzow, M.R

Get full text

Peripheral Blood CD34 Count Can Predict Successful Progenitor Cell Mobilization in Poor Mobiliziers Treated With Plerixafor and G-CSF by Micallef, I.N, Maurer, M, Ansell, S.M, Buadi, F, Dispenzieri, A, Gastineau, D.A, Gertz, M.A, Hayman, S.R, Hogan, W.J, Inwards, D.J, Johnston, P.B, Kumar, S, Lacy, M.Q, Litzow, M.R, Porrata, L.F, Winters, J.L, Marzolf, M, Shaw, T, Calandra, G

Get full text

Clinical Outcomes With and Without Sargramostim (GM-CSF) Post Autologous Peripheral Blood Stem Cell Transplantation by Howle, E.L, Wolf, R.C, Burzynski, J.A, Gastineau, D.A, Lacy, M.Q, Gertz, M.A, Dispenzieri, A, Kumar, S, Dingli, D, Buadi, F, Inwards, D.J, Ansell, S.M, Micallef, I.N.M, Johnston, P.B, Porrata, L.F, Elliott, M.A, Hogan, W.J, Litzow, M.R

Get full text

Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma by Porrata, L F, Rsitow, K, Inwards, D J, Ansell, S M, Micallef, I N, Johnston, P B, Habermann, T M, Witzig, T E, Colgan, J P, Nowakowski, G S, Thompson, C A, Markovic, S N

“…A specific predictor during routine follow-up to ascertain risk for relapse after standard chemotherapy in non-Hodgkin's lymphoma (NHL) has not been…”
Get full text

The impact of smoking on outcomes among patients undergoing hematopoietic SCT for the treatment of acute leukemia by Ehlers, S L, Gastineau, D A, Patten, C A, Decker, P A, Rausch, S M, Cerhan, J R, Hogan, W J, Ebbert, J O, Porrata, L F

“…A paucity of research exists examining the potential impact of tobacco use on cancer treatment outcomes, especially among patients treated with hematopoietic…”
Get full text

255: Rescue Mobilization of Hematopoietic Progenitor Cells with AMD3100 + G-CSF is Successful in Patients Who Previously Failed Mobilization by Micallef, I.N.M, Ansell, S.M, Buadi, F, Dispenzieri, A, Elliott, M.A, Gertz, M.A, Hayman, S.R, Hogan, W.J, Inwards, D.J, Gastineau, D.A, Johnston, P.B, Kumar, S, Lacy, M.Q, Porrata, L.F, Marzolf, M, Shaw, T, Winters, J.L, Calandra, G, Litzow, M.R

Get full text

87: Peripheral Blood Stem Cell Transplant for POEMS Syndrome is Associated with High Rates of Engraftment Syndrome by Dispenzieri, A, Lacy, M.Q, Hayman, S.R, Kumar, S.K, Buadi, F, Dingli, D, Litzow, M.R, Gastineau, D.A, Inwards, D.J, Elliott, M.A, Micallef, I.N, Ansell, S.M, Hogan, W.J, Porrata, L.F, Johnston, P.B, Afessa, B, Bryce, A, Kyle, R.A, Gertz, M.A

Get full text

cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies by Holtan, S.G, Hogan, W.J, Elliott, M.A, Ansell, S.M, Inwards, D.J, Porrata, L.F, Johnston, P.B, Micallef, I.N, Lacy, M.Q, Gastineau, D.A, Litzow, M.R

“…The combination of fludarabine and melphalan as a reduced-intensity conditioning (RIC) regimen extends allogeneic hematopoietic SCT (HSCT) as a therapeutic…”
Get full text

Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia by PORRATA, L. F, LITZOW, M. R, TEFFERI, A, LETENDRE, L, KUMAR, S, GEYER, S. M, MARKOVIC, S. N

“…Absolute lymphocyte count (ALC) recovery correlates with survival after autologous hematopoietic stem cell transplantation (AHSCT) for patients with multiple…”
Get full text